[Use of Longidaza in chronic prostatitis: A systematic review and meta-analysis]

Chronic bacterial prostatitis (CBP) is a disease with a multifaceted pathophysiological basis, including infectious, immunological, neurological, vascular, endocrinological, biochemical, and psychological factors, making it a multidisciplinary problem. One current treatment strategy is the use of the original drug Longidaza, which has demonstrated efficacy in this disease, primarily due to its anti-inflammatory effect. A large number of original studies necessitate systematization of the results.

To conduct a comprehensive assessment of the clinical efficacy of Longidaza (bovhyaluronidase azoximer) when included in the treatment plan for chronic prostatitis, based on data from controlled clinical trials.

A systematic review and meta-analysis were conducted according to the PRISMA protocol. Elibrary, PubMed, and Cyberleninka databases were used to search for articles. The search was conducted using a combination of keywords: chronic prostatitis and "Longidaza," "Bovhyaluronidase azoximer," among studies published no later than August 31, 2025.

A search of scientific databases using the algorithms illustrated in Figure 1 yielded a total of 210 publications, of which 10 studies were then selected based on inclusion/exclusion criteria.

The results of the analysis suggest that adding Longidaza to standard therapy for chronic prostatitis (antimicrobial and anti-inflammatory agents) significantly reduces clinical manifestations of the disease. Furthermore, the inclusion of Longidaza in the treatment plan reduces inflammation in the prostate gland and improves maximum urinary flow rate, resulting in a significant reduction in the severity of chronic prostatitis.